Kanser tedavilerinin anla\u015f\u0131lmas\u0131nda \u00f6nemli bir ilerleme, tim\u00fcs\u00fcn durumunun imm\u00fcnoterapilerin ba\u015far\u0131s\u0131nda kilit bir rol oynad\u0131\u011f\u0131n\u0131 ortaya koyuyor. Yeti\u015fkinlerde s\u0131k\u00e7a g\u00f6z ard\u0131 edilen bu organ, t\u00fcm\u00f6rleri hedef alan T lenfositlerinin olgunla\u015fmas\u0131 i\u00e7in hayati \u00f6neme sahiptir. Yak\u0131n zamanda yap\u0131lan bir \u00e7al\u0131\u015fma, tim\u00fcs\u00fc daha sa\u011fl\u0131kl\u0131 olan hastalar\u0131n, kanser t\u00fcr\u00fc ne olursa olsun, imm\u00fcnoterapilere daha iyi yan\u0131t verdiklerini g\u00f6steriyor.<\/p>\n
Ara\u015ft\u0131rmac\u0131lar, akci\u011fer, melanom ve b\u00f6brek kanseri dahil olmak \u00fczere \u00e7e\u015fitli kanserlere sahip 3.400’den fazla hastay\u0131 analiz etti. G\u00f6\u011f\u00fcs taray\u0131c\u0131lar\u0131na uygulanan yapay zeka y\u00f6ntemiyle tim\u00fcs sa\u011fl\u0131\u011f\u0131n\u0131 de\u011ferlendirdiler. Sonu\u00e7lar, daha aktif bir tim\u00fcse sahip ki\u015filerin hastal\u0131\u011f\u0131n ilerleme riskinin daha d\u00fc\u015f\u00fck oldu\u011funu ve ya\u015fam s\u00fcresinin uzad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Bu ili\u015fki, tedavilere yan\u0131t\u0131 tahmin etmek i\u00e7in s\u0131k\u00e7a kullan\u0131lan t\u00fcm\u00f6r mutasyon y\u00fck\u00fc veya PD-L1 proteini ifadesi gibi di\u011fer belirte\u00e7ler dikkate al\u0131nd\u0131\u011f\u0131nda bile devam ediyor.<\/p>\n
Tim\u00fcs, \u00e7e\u015fitli bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 i\u00e7in gerekli olan saf T lenfositlerini \u00fcretir. Sa\u011fl\u0131kl\u0131 tim\u00fcse sahip hastalarda, kan ve t\u00fcm\u00f6rlerde daha geni\u015f \u00e7e\u015fitte T h\u00fccre resept\u00f6rleri g\u00f6zleniyor; bu da daha g\u00fc\u00e7l\u00fc bir ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin i\u015faretidir. \u00d6te yandan, ya\u015f veya \u00f6nceki tedavilere ba\u011fl\u0131 olarak zay\u0131flam\u0131\u015f bir tim\u00fcs, bu savunma yetene\u011fini s\u0131n\u0131rl\u0131yor.<\/p>\n
Bu ke\u015fif, tim\u00fcs sa\u011fl\u0131\u011f\u0131n\u0131n de\u011ferlendirilmesinin, tedavileri ki\u015fiselle\u015ftirmek i\u00e7in standart bir ara\u00e7 haline gelebilece\u011fini \u00f6ne s\u00fcr\u00fcyor. Ayr\u0131ca, tim\u00fcs\u00fc yenilemeye y\u00f6nelik stratejilerin kap\u0131s\u0131n\u0131 aral\u0131yor ve b\u00f6ylece imm\u00fcnoterapilerin etkinli\u011fini art\u0131r\u0131yor. Mevcut biyobelirte\u00e7lerin aksine t\u00fcm\u00f6re odaklanan bu yakla\u015f\u0131m, kanserle m\u00fccadelede hastan\u0131n genel durumunu dikkate alarak daha kapsaml\u0131 bir bak\u0131\u015f a\u00e7\u0131s\u0131 sunuyor.<\/p>\n
DOI\u00a0:<\/strong> https:\/\/doi.org\/10.1038\/s41586-026-10243-x<\/a><\/p>\n Titre\u00a0:<\/strong> Thymic health and immunotherapy outcomes in patients with cancer<\/p>\n Revue : <\/strong> Nature<\/p>\n \u00c9diteur : <\/strong> Springer Science and Business Media LLC<\/p>\n Auteurs : <\/strong> Simon Bernatz; Vasco Prudente; Suraj Pai; Asbj\u00f8rn K. Attermann; Alessandro Di Federico; Andrew Rowan; Selvaraju Veeriah; Lars Dyrskj\u00f8t; Leonard N\u00fcrnberg; Joao V. Alessi; Patrick A. Ott; Elad Sharon; Allan Hackshaw; Nicholas McGranahan; Christopher Abbosh; Raymond H. Mak; Danielle Bitterman; Mark Awad; Biagio Ricciuti; Charles Swanton; Mariam Jamal-Hanjani; Nicolai J. Birkbak; Hugo J. W. L. Aerts<\/p>\n","protected":false},"excerpt":{"rendered":" Tim\u00fcs, kanser imm\u00fcnoterapilerinin etkinli\u011fini etkiler mi? Kanser tedavilerinin anla\u015f\u0131lmas\u0131nda \u00f6nemli bir ilerleme, tim\u00fcs\u00fcn durumunun imm\u00fcnoterapilerin ba\u015far\u0131s\u0131nda kilit bir rol oynad\u0131\u011f\u0131n\u0131 ortaya koyuyor. Yeti\u015fkinlerde s\u0131k\u00e7a g\u00f6z ard\u0131 edilen bu organ, t\u00fcm\u00f6rleri hedef alan T lenfositlerinin olgunla\u015fmas\u0131 i\u00e7in hayati \u00f6neme sahiptir. Yak\u0131n zamanda yap\u0131lan bir \u00e7al\u0131\u015fma, tim\u00fcs\u00fc daha sa\u011fl\u0131kl\u0131 olan hastalar\u0131n, kanser t\u00fcr\u00fc ne olursa olsun, imm\u00fcnoterapilere… Okumaya devam et Tim\u00fcs, kanser imm\u00fcnoterapilerinin etkinli\u011fini etkiler mi?<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,3,2],"tags":[],"class_list":["post-17","post","type-post","status-publish","format-standard","hentry","category-bilim-teknoloji","category-insan-insani","category-saglik","entry"],"_links":{"self":[{"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/posts\/17","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/comments?post=17"}],"version-history":[{"count":1,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/posts\/17\/revisions"}],"predecessor-version":[{"id":18,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/posts\/17\/revisions\/18"}],"wp:attachment":[{"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/media?parent=17"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/categories?post=17"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biologistjournal.com\/tr\/wp-json\/wp\/v2\/tags?post=17"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}